99% Purity Meloxicam Pharmaceutical Meloxicam Powder Material Meloxicam

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung-Meloxicam
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Meloxicam
• Name: Meloxicam Powder
• Appearance: Yellow Powder
• Color: Yellow Color
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Treatment Rheumatoid Arthritis
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 71125-38-7
• Mf: C14h13n3o4s2
• MW: 351.40072
• Density: 1.613
• Melting Point: 255c
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 5000kg/Month

Product Description

99% Purity Meloxicam Pharmaceutical Meloxicam Powder Material Meloxicam 

Product Description

Product Details

Product name	Meloxicam
Cas number	71125-38-7
Apperance	Light Yellow to Yellow Powder
Density	1.613
MF	C14H13N3O4S2
Melting point	255°C
MW	351.40072

Meloxicam is a non-steroid antipyretic, analgesic and anti-inflammatory drug. It is not a hormone drug and has strong anti-inflammatory, analgesic and antipyretic effects. It can selectively inhibit the activity of cyclocxygenase-2 (COX-2), thereby blocking the synthesis of prostaglandins. The inhibition of prochemicalbook adenosin biosynthesis in inflammatory sites was stronger than that of prostaglandin biosynthesis in gastric mucosa or kidney, and was safer than other NSAIDs. It is mainly used to relieve the symptoms of osteoarthritis, painful osteoarthritis, rheumatoid arthritis and severe spondylitis of the joints.

Application&Function

Older patients and patients with an increased risk of adverse reactions;
In elderly patients, patients with rheumatoid arthritis and ankylosing spondylitis treatment recommended dose for 7.5mg/days. Starting dose in patients with increased risk of adverse reactions to 7.5mg/days.
Patients with renal insufficiency:
Patients with severe renal failure and need dialysis, the dose should not exceed 7.5mg/days.
Patients with mild to moderate renal insufficiency do not need to adjust the dosage (such as patients with creatinine clearance greater than 25ml/minutes).
Patients with severe renal failure without dialysis.
Patients with hepatic insufficiency: In patients with mild and moderate hepatic insufficiency no need to adjust the dose.
In patients with severe hepatic insufficiency.
Children: This product is not for use in children under 15 years of age. Meloxicam has other forms, may apply.

Specification